Anupam Rasayan-Bliss GVS deal: ₹299 open offer closes 2026

The latest update in the Bliss GVS transaction

Anupam Rasayan India Ltd has completed its mandatory open offer process for Bliss GVS Pharma Ltd, acquiring a nominal number of shares from public shareholders. The company acquired 1,669 fully paid-up equity shares at an offer price of ₹299 per share, as disclosed in open offer completion details. The total consideration paid for these shares was ₹4,99,031. The acquisition is described as representing 0.00% of the expanded voting share capital of Bliss GVS Pharma.

The open offer sits within a larger, multi-step transaction in which Anupam Rasayan has announced plans to acquire control and a significant equity stake in the Mumbai-based formulations company. Earlier disclosures and media reports put the core acquisition at around ₹1,369.51 crore for a 43.30% stake, with a further open offer for an additional 26% stake at the same price per share. Separately, the acquisition was also described as involving a consideration of about ₹1,600 crore and expected to close in September 2026.

What Anupam Rasayan acquired through the open offer

The tendering outcome indicates limited participation from public shareholders during the open offer window. On close of the offer, 1,669 shares were tendered, which was also reported as 0.00158% stake in Bliss GVS Pharma. The price paid was ₹299 per share, consistent with the price disclosed for the broader transaction.

Anupam Rasayan’s disclosure also states that it completed the acquisition of a 0.001% stake in Bliss GVS Pharma for ₹0.05 crore (₹0.5 million) on August 10, 2026. The date aligns with the revised closing date of the tendering period. The number of shares, tender price, and consideration amount provide a clear picture of the open offer’s practical impact: it was completed, but it resulted in only a nominal incremental stake from public shareholders.

Revised tendering period after SEBI observations

Anupam Rasayan, along with its person acting in concert (PAC) Mates Visa Consultancy Private Limited, updated the schedule for the open offer after SEBI’s final observations. The tendering period was revised to July 28 to August 10, 2026. The company also disclosed that the open offer was for up to 2,77,26,848 shares, representing 26.00% of the expanded voting share capital, at ₹299 per equity share.

The open offer mechanism was triggered after Anupam Rasayan’s acquisition of control in Bliss GVS through the purchase of 4,58,03,024 equity shares, which was disclosed as representing 43.11% of the target company’s capital. In another disclosure, Anupam Rasayan said it had agreed to acquire a 43.30% stake in Bliss GVS for ₹1,369.51 crore, equating to ₹299 per share, under a Share Purchase Agreement dated May 23, 2026.

Deal size and stake: what has been announced

The acquisition has been described in multiple disclosures and reports with a consistent core structure: a large initial stake purchase at ₹299 per share, followed by a mandatory open offer at the same price. Reports also stated Anupam Rasayan signed a deal to acquire 43.3% of Bliss GVS for ₹1,369.51 crore at ₹299 per share, and that a mandatory open offer for an additional 26% could take the total potential stake to 74.2%.

The total transaction value for up to 74.20% equity was reported at approximately ₹2,198.54 crore (also cited as roughly ₹2,199 crore in another report). Anupam Rasayan’s Managing Director Anand Desai was cited by Press Trust of India as saying the company had entered into a definitive agreement for the transaction and would also launch the mandatory open offer for public shareholders.

Funding structure disclosed for the acquisition

Anupam Rasayan’s regulatory filing and subsequent coverage outlined a funding mix for the initial stake purchase. The ₹1,369 crore level transaction was disclosed as being financed through a combination of a ₹300 crore term loan and a non-controlling, non-voting equity instrument for the remainder.

This funding description has been repeated across reports tied to the May 23, 2026 announcement. While the open offer itself resulted in a small number of shares being tendered, the broader transaction remains centered on the much larger promoter and public shareholder stake purchase arrangements set out in the Share Purchase Agreement and related filings.

Operational focus: utilisation improvement targets at Bliss

Alongside the ownership changes, management has indicated an operational improvement agenda for Bliss GVS. Management is targeting an increase in Bliss utilisation from about 30% to 60-70% over two to three years. The utilisation target suggests a focus on scaling output and improving capacity usage following the acquisition, although the disclosures do not provide detailed capex plans or plant-level actions.

The transaction has also been described as a step toward deeper integration across the pharma and chemicals value chain, with Anupam Rasayan seeking a broader platform spanning advanced chemistries and finished formulations. These positioning statements were made in the context of the deal announcement and the strategic rationale shared around it.

Stock market reaction around the announcement

Bliss GVS Pharma shares hit the 20% upper circuit on the day coverage highlighted Anupam Rasayan’s plan to acquire up to a 43.3% stake for ₹1,369.51 crore. That move was directly linked in reports to the acquisition announcement and the price per share disclosed for the transaction.

Shares of Anupam Rasayan were also described as witnessing volatile trading after the deal announcement. The available information does not quantify the move in Anupam Rasayan’s stock, but it ties the volatility to the market digesting the acquisition structure, funding plan, and the company’s stated intent to expand across the pharmaceutical value chain.

Key facts at a glance

Why this matters for investors tracking pharma and specialty chemicals

The Bliss GVS acquisition is being positioned as a cross-segment move linking specialty chemicals and formulations, with the disclosed structure combining a large negotiated stake purchase and a mandatory open offer. The completion of the open offer, even with minimal shares tendered, closes one procedural leg of the transaction timetable as disclosed.

The operational target to lift utilisation from about 30% to 60-70% over two to three years is a measurable yardstick investors are likely to track over time. Separately, the acquisition timeline has been discussed as expected to close within six months in one report, and as expected to close in September 2026 in another line item describing the transaction’s expected schedule.

Conclusion

Anupam Rasayan has completed its Bliss GVS open offer at ₹299 per share, acquiring 1,669 shares for a total of ₹0.0499 crore. The larger transaction remains centered on the agreed purchase of roughly a 43% stake at ₹299 per share and the potential to raise ownership further through the mandatory open offer framework. The deal has been described as expected to close in September 2026, while management has also set a target to raise Bliss utilisation from about 30% to 60-70% over two to three years.